Adjunctive Study of AL-37807 Ophthalmic Suspension

Phase 2CompletedNCT00620256

Alcon Research129 enrolled

Overview

The purpose of the study is to compare the safety and intraocular pressure-lowering efficacy of AL-37807 ophthalmic suspension vs. Timolol gel forming solution vs. AL-37807 vehicle, all dosed concomitantly with Xalatan, in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

129

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

AL-37807 ophthalmic suspension, 0.1%DRUG

Timolol gel forming solution, 0.5%DRUG

AL-37807 ophthalmic solution vehicleOTHER

Latanoprost ophthalmic solution

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Open-angle glaucoma * Ocular hypertension * Must have been on Xalatan for at least 3 months * VA not worse than 0.60 * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Age related * Other protocol-defined exclusion criteria may apply

Locations (1)

Contact Alcon Call Center at 1-888-451-3937

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean change from baseline in intraocular pressure

Time frame: Baseline, up to 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.